| Literature DB >> 10608784 |
S Kohl1, E D Charlebois, M Sigouroudinia, C Goldbeck, K Hartog, R E Sekulovich, A G Langenberg, R L Burke.
Abstract
The humoral response to a herpes simplex virus (HSV) type 2 subunit vaccine containing recombinant glycoproteins B (gB2) and D (gD2) was tested in 3 groups of patients. These included HSV-seronegative, HSV-1-seropositive, and HSV-2-seropositive individuals. There were excellent antibody responses, as measured by gB2- and gD2-specific ELISAs and HSV-2 neutralization assays. However, in 2 HSV-2 antibody-dependent cellular cytotoxicity (ADCC) assays, there were relatively low antibody responses, especially among HSV-seronegative individuals. The low ADCC responses may be associated with the poor efficacy of this vaccine observed in clinical trials.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10608784 DOI: 10.1086/315208
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226